WP
DSGN icon

Woodline Partners’s Design Therapeutics DSGN Stock Holding History

Woodline Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Buy
961,501
+17,462
+2% +$177K 0.04% 504
2025
Q4 		$8.86M Buy
944,039
+331,327
+54% +$2.59M 0.03% 488
2025
Q3 		$4.61M Sell
612,712
-164,825
-21% -$826K 0.02% 587
2025
Q2 		$2.62M Buy
777,537
+131,843
+20% +$493K 0.01% 683
2025
Q1 		$2.49M Buy
+645,694
New +$3.08M 0.02% 634

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners's DSGN Position: Q1 2026 in Review

Woodline Partners increased its Design Therapeutics (DSGN) stake by 1.8% in Q1 2026, buying an estimated $177K and bringing the position to 961,501 shares worth $10.2M. The position accounts for 0.04% of the portfolio, ranked #504.

Woodline Partners first reported a position in DSGN in Q1 2025 and has held it in 5 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Woodline Partners held 961,501 shares of Design Therapeutics worth $10.2M as of Q1 2026.
  • Woodline Partners bought 17,462 Design Therapeutics shares in Q1 2026, an estimated $177K.
  • Design Therapeutics made up 0.04% of Woodline Partners's portfolio in Q1 2026, its #504 holding.
  • Woodline Partners first reported a position in Design Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.